Camurus Earns Marketing Authorization for Oczyesa® in the EU
Today marks a significant step for patients with acromegaly as Camurus announces that the European Commission has granted marketing authorization for Oczyesa®, a groundbreaking treatment option. This once-monthly subcutaneous depot of octreotide enhances management of acromegaly, a rare and chronic disease.
Innovative Treatment for Acromegaly
Oczyesa® is designed for convenient self-administration, allowing patients to manage their treatment effectively with a pre-filled autoinjector pen. The unique formulation utilizes Camurus' proprietary FluidCrystal® technology, ensuring sustained delivery and optimal therapy adherence.
Understanding Acromegaly
Acromegaly arises from an excess of growth hormone, typically caused by a pituitary tumor, resulting in abnormal growth of bones and tissues. It often leads to enlarged facial features, hands, and feet, and can significantly impair the quality of life due to its various symptoms such as fatigue, joint pain, and headaches.
The Impact of Oczyesa®
Fredrik Tiberg, President & CEO of Camurus, expressed enthusiasm about making Oczyesa® available to those in need. Clinical trials, including the ACROINNOVA program, demonstrated that Oczyesa® leads to effective disease control with improved symptoms and quality of life for patients. Initial results show promising stabilization of insulin growth factor-1 (IGF-1) levels in treated patients.
Clinical Study Highlights
The marketing authorization is based on an extensive clinical program that includes seven clinical studies, showcasing two pivotal Phase 3 trials. The ACROINNOVA 1 study indicated that patients treated with Oczyesa® achieved higher rates of normalized IGF-1 levels compared to those on placebo. Additionally, sustained improvements in symptoms were noted over a 52-week period in the ACROINNOVA 2 study, aligning with better overall life quality and treatment satisfaction.
Projected Outcomes
Experts emphasize the importance of Oczyesa® as a reliable therapy for patients. Dr. Diego Ferone, noted for his contributions in endocrinology, highlighted that patients should expect not only effective disease management but also improved self-administration options, freeing them from frequent visits for injections.
Camurus' Commitment to Patient Care
As Camurus continues to innovate within the biopharmaceutical field, their focus remains on patient-centered solutions aimed at enhancing treatment effectiveness and convenience. Their product pipeline extends beyond acromegaly, exploring potential in treating other serious conditions like gastroenteropancreatic neuroendocrine tumors and polycystic liver disease.
Looking Ahead
The approval of Oczyesa® represents a vital addition to the treatment landscape for acromegaly. With its unique preparation and administration method, it stands poised to change the lives of many patients within the EU. Camurus aims to initiate product availability swiftly, ensuring those affected can benefit from this innovative therapy.
Frequently Asked Questions
What is Oczyesa® and what condition does it treat?
Oczyesa® is a once-monthly subcutaneous depot of octreotide developed by Camurus for the maintenance treatment of acromegaly in adult patients.
How does Oczyesa® work?
Oczyesa® helps to regulate growth hormone levels and improve symptoms associated with acromegaly, enhancing patients' quality of life.
Who can use Oczyesa®?
Oczyesa® is indicated for adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.
What benefits does the self-administration format offer?
The pre-filled autoinjector pen allows patients to administer their medication easily and confidently at home, improving adherence to treatment.
Is this treatment available now?
Camurus is working to make Oczyesa® available in the EU as soon as possible following its marketing authorization.
